These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 31843790)

  • 1. Prevalence and characteristics of macular atrophy in eyes with neovascular age-related macular degeneration. A study from a long-term observational dataset: the Fight Retinal Blindness! project.
    Daien V; Nguyen V; Essex RW; Guymer R; Arnold JJ; Munk M; Ceklic L; Gillies MC; Barthelmes D;
    Br J Ophthalmol; 2020 Aug; 104(8):1064-1069. PubMed ID: 31843790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study.
    Spooner KL; Fraser-Bell S; Cozzi M; Staurenghi G; Invernizzi A; Monteduro D; Munk MR; Hong T; Chang AA
    Ophthalmology; 2020 Dec; 127(12):1663-1673. PubMed ID: 32544561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study).
    Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Pecheur FL; Munk MR; McAllister IL
    Ophthalmology; 2020 Feb; 127(2):198-210. PubMed ID: 31619357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intralesional Macular Atrophy in Anti-Vascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration in the IVAN Trial.
    Bailey C; Scott LJ; Rogers CA; Reeves BC; Hamill B; Peto T; Chakravarthy U; Harding SP;
    Ophthalmology; 2019 Jan; 126(1):75-86. PubMed ID: 30301555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macular Atrophy Affecting Visual Outcomes in Patients Undergoing Anti-VEGF Treatment in Routine Clinical Practice.
    Rieveschl NB; Song W; Li A; Conti TF; Hom GL; Tsai GJ; Conti FF; Babiuch AS; Singh RP
    Ophthalmic Surg Lasers Imaging Retina; 2020 Feb; 51(2):68-75. PubMed ID: 32084278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration.
    Munk MR; Ceklic L; Ebneter A; Huf W; Wolf S; Zinkernagel MS
    Acta Ophthalmol; 2016 Dec; 94(8):e757-e764. PubMed ID: 27417506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
    Sadda SR; Tuomi LL; Ding B; Fung AE; Hopkins JJ
    Ophthalmology; 2018 Jun; 125(6):878-886. PubMed ID: 29477692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spectral-Domain OCT-Based Prevalence and Progression of Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
    Gune S; Abdelfattah NS; Karamat A; Balasubramanian S; Marion KM; Morgenthien E; Sadda SR
    Ophthalmology; 2020 Apr; 127(4):523-532. PubMed ID: 31718842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
    Gillies MC; Nguyen V; Daien V; Arnold JJ; Morlet N; Barthelmes D
    Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PROGRESSION OF MACULAR ATROPHY IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION UNDERGOING ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
    Abdelfattah NS; Zhang H; Boyer DS; Sadda SR
    Retina; 2016 Oct; 36(10):1843-50. PubMed ID: 27135213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ;
    Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macular atrophy development in neovascular age-related macular degeneration during first year of treatment: Incidence and risk factors.
    Oliveira MA; Farinha C; Rodrigues TM; Martins A; Cachulo MDL; Marques JP; Pires I; Silva R
    Eur J Ophthalmol; 2021 Mar; 31(2):521-528. PubMed ID: 32103681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subretinal fluid may protect against macular atrophy in neovascular age-related macular degeneration: 5 years of follow-up from Fight Retinal Blindness registry.
    Sánchez-Monroy J; Nguyen V; Puzo M; Calvo P; Arruabarrena C; Monaco P; Chilov M; Keegan D; Barthelmes D; Gillies M
    Acta Ophthalmol; 2023 Jun; 101(4):457-464. PubMed ID: 36536538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Outcomes of Ranibizumab versus Aflibercept for Neovascular Age-Related Macular Degeneration: Data from the Fight Retinal Blindness! Registry.
    Bhandari S; Nguyen V; Arnold J; Young S; Banerjee G; Gillies M; Barthelmes D
    Ophthalmology; 2020 Mar; 127(3):369-376. PubMed ID: 31757494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between neovascular lesion type and clinical characteristics of nonneovascular fellow eyes in patients with unilateral, neovascular age-related macular degeneration.
    Marsiglia M; Boddu S; Chen CY; Jung JJ; Mrejen S; Gallego-Pinazo R; Freund KB
    Retina; 2015 May; 35(5):966-74. PubMed ID: 25627089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics that Correlate with Macular Atrophy in Ranibizumab-Treated Patients with Neovascular Age-Related Macular Degeneration.
    Staurenghi G; Cozzi M; Sadda S; Hill L; Gune S
    Ophthalmol Retina; 2023 Apr; 7(4):300-306. PubMed ID: 36372347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Vazquez-Alfageme C; Nicholson L; Hamilton RD; Patel PJ
    Retina; 2019 Apr; 39(4):664-669. PubMed ID: 29324593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and Progression of Nongeographic Atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Clinical Trial.
    Daniel E; Maguire MG; Grunwald JE; Toth CA; Jaffe GJ; Martin DF; Ying GS;
    JAMA Ophthalmol; 2020 May; 138(5):510-518. PubMed ID: 32191267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topographic Correspondence of Macular Atrophy With Choroidal Neovascularization in Ranibizumab-treated Eyes of the TREX-AMD Trial.
    Abdelfattah NS; Hariri AH; Al-Sheikh M; Pitetta S; Ebraheem A; Wykoff CC; Sadda SR;
    Am J Ophthalmol; 2018 Aug; 192():84-90. PubMed ID: 29763612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced Vessel Density of the Choriocapillaris during Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration.
    Hikichi T; Agarie M
    Invest Ophthalmol Vis Sci; 2019 Mar; 60(4):1088-1095. PubMed ID: 30901385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.